Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Apr;10(1-2):54-66.
doi: 10.1007/s11864-009-0100-x. Epub 2009 Apr 21.

Current status on biologic therapies in the treatment of epithelial ovarian cancer

Ernest S Han  1 , Paul Lin, Mark Wakabayashi
Affiliations
Review

Current status on biologic therapies in the treatment of epithelial ovarian cancer

Ernest S Han et al. Curr Treat Options Oncol. 2009 Apr.

Abstract

Treatment of epithelial ovarian cancer generally involves surgical staging followed by chemotherapy with a combination of a platinum and a taxane-containing agent. However, a majority of patients recur and ultimately succumb to their cancer. Novel therapies that target specific pathways involved in ovarian tumorigenesis are rapidly emerging. In ovarian cancer, targeted therapies have focused on both the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways. Single-agent bevacizumab, a VEGF inhibitor, demonstrated significant clinical activity in multiple phase II studies. Various combinations of cytotoxic and biologic agents with bevacizumab as well as newer anti-angiogenesis agents are being tested. In contrast, EGFR inhibitors have not shared the same clinical activity in epithelial ovarian cancers as compared to the VEGF inhibitors. Translational studies are needed to help design rational combinations of targeted agents and to help predict response to therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mol Cancer Ther. 2008 Oct;7(10):3129-40 - PubMed
    1. Gynecol Oncol. 2007 Apr;105(1):3-6 - PubMed
    1. Gynecol Oncol. 2008 Aug;110(2):140-5 - PubMed
    1. Cancer Treat Rev. 2008 Feb;34(1):37-48 - PubMed
    1. J Clin Oncol. 2001 Feb 15;19(4):1001-7 - PubMed

MeSH terms

LinkOut - more resources